FDA Facility Issue May Delay Regeneron's EYLEA HD Launch
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
/ 2 items
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
Garetosmab is a new drug for FOP, a rare disease where muscles turn to bone. In trials, it dramatically cut new abnormal bone growth by over 90%. This could be a major breakthrough, and Regeneron aims for U.S. approval by late 2025.